Ernexa Therapeutics Inc. Warrants closed at $0.04 on Sep 24, up 11.11%, 80.5% below its highest close since Feb 6. Volume of 851 shares was 0.03× its 20-day average (below normal).
Split-adjusted performance: -55.1% over one month.
Short interest was 1.9K shares at the Sep 15 settlement, up 169.2% from the prior report (1.0 days to cover).
No reported quarters with price history yet.
Percentile among 423 companies (100 = best)
Industry medians: 6-month return −2.9%, revenue growth +6.4%, net margin −41.2%, P/E 16.2×.
No recent articles focused on Ernexa Therapeutics Inc. Warrants.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
